PMEL and toxic epidermal necrolysis: Skin toxicities, an on-target reaction to gp100-expressing melanocytes, were frequent—rash and pruritus, each 83%, dry skin 64%, pigment or erythema changes 57%—yet two-thirds were grade 1–2, presented within the first few doses, and responded to antihistamines or topical corticosteroids, with no cases of Stevens–Johnson syndrome or toxic epidermal necrolysis.